The Federal Trade Commission has approved early termination of the required waiting period for a pending license of a BioCryst Pharmaceuticals Inc. compound by Roche. The licensing agreement, which Birmingham-based BioCryst (NASDAQ: BCRX - News) announced three weeks ago, grants to Roche the exclusive rights to develop and commercialize the compound, known as “BCX-4208,” which is used to help prevent the rejection of transplanted organs and for the treatment of autoimmune diseases.
